HRT Financial’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

HRT Financial’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-74,907	Closed	-$755K	–	3550
2022 Q4	$755K	Hold	74,907	–	–	0.01%	1152
2022 Q3	$742K	Hold	74,907	–	–	0.01%	1149
2022 Q2	$731K	Hold	74,907	–	–	0.01%	1218
2022 Q1	$731K	Hold	74,907	–	–	0.01%	1346
2021 Q4	$741K	Hold	74,907	–	–	﹤0.01%	1434
2021 Q3	$744K	Hold	74,907	–	–	﹤0.01%	1610
2021 Q2	$747K	Sell	74,907 -5,224	-7%	-$52.3K	0.01%	1411
2021 Q1	$805K	Buy	+80,131	New	+$801K	0.01%	1348

HRT Financial's EBACU Position: Q1 2023 in Review

HRT Financial sold out of European Biotech Acquisition Corp. Units (EBACU) in Q1 2023, closing a stake of 74,907 shares — an estimated $755K sold.

HRT Financial first reported a position in EBACU in Q1 2021 and held it in 8 quarters. The position peaked at $805K in Q1 2021. 0 funds tracked by Wall St. Rank hold EBACU as of Q1 2023.

HRT Financial reported no remaining European Biotech Acquisition Corp. Units position as of Q1 2023 after selling out during the quarter.
HRT Financial sold 74,907 European Biotech Acquisition Corp. Units shares in Q1 2023, an estimated $755K.
HRT Financial first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 8 quarters.
HRT Financial's European Biotech Acquisition Corp. Units position peaked at $805K in Q1 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.